

DAFTAR PUSTAKA

- Al-Fattani, M. (2006). Biofilm matrix of *Candida albicans* and *Candida tropicalis*: chemical composition and role in drug resistance. *Journal of Medical Microbiology*, 55(8), pp.999-1008.
- Al-Kadhemy, Mahasin. (2012). Absorption and Fluorescence Spectra of Crystal Violet Doped PS and PMMA Blend Films. *Atti della Fondazione Giorgio Ronchi*. 5. 735.
- Ann Chai, L., Denning, D. and Warn, P. (2010). *Candida tropicalis* in human disease. *Critical Reviews in Microbiology*, 36(4), pp.282-298.
- Anonim (2019). Centers for Disease Control and Prevention. [Online] CDC.gov. Diakses melalui: <https://www.cdc.gov/fungal/diseases/candidiasis/invasive/> [Accessed 17 Dec. 2019].
- Anonim (2019). MIMS. [Online] mims.com. Diakses melalui: <https://www.mims.com/indonesia/drug/info/fluconazole/fluconazole?type=brief&mtype=generic> [Accessed 17 Dec. 2019].
- Bergsson, G., Arnfinnsson, J., Steingrimsson, O. and Thormar, H. (2001). In Vitro Killing of *Candida albicans* by Fatty Acids and Monoglycerides. *Antimicrobial Agents and Chemotherapy*, 45(11), pp.3209-3212.

- Bernardes, E., Lewenza, S. and Reckseidler-Zenteno, S. (2015). Current Research Approaches to Target Biofilm Infections. *Journal of Post Doctoral Research*, 3(6).
- Bizerra, F., Nakamura, C., De Poersch, C., Estivalet Svidzinski, T., Borsato Quesada, R., Goldenberg, S., Krieger, M. and Yamada-Ogatta, S. (2008). Characteristics of biofilm formation by *Candida tropicalis* and antifungal resistance. *FEMS Yeast Research*, 8(3), pp.442-450.
- Blandin, G., Ozier-Kalogeropoulos, O., Wincker, P., Artiguenave, F. and Dujon, B. (2000). Genomic Exploration of the *Hemiascomycetous* Yeasts: 16. *Candida tropicalis*. *FEBS Letters*, 487(1), pp.91-94.
- Chandra, J., Kuhn, D., Mukherjee, P., Hoyer, L., McCormick, T. and Ghannoum, M. (2001). Biofilm Formation by the Fungal Pathogen *Candida albicans*: Development, Architecture, and Drug Resistance. *Journal of Bacteriology*, 183(18), pp.5385-5394.
- Chatrath, A., Gangwar, R., Kumari, P. and Prasad, R. (2019). In Vitro Anti-Biofilm Activities of Citral and Thymol Against *Candida Tropicalis*. *Journal of Jamur*, 5(1), p.13.
- Clinical & Laboratory Standards Institute (CLSI). (2018). M100 Performance Standards for Antimicrobial. Wayne, PA: *Clinical and Laboratory Standards Institute*.

Desai, J., Mitchell, A. and Andes, D. (2014). Fungal Biofilms, Drug Resistance, and Recurrent Infection. *Cold Spring Harbor Perspectives in Medicine*, 4(10), pp.a019729-a019729.

Desai, J., Mitchell, A. and Andes, D. (2014). Fungal Biofilms, Drug Resistance, and Recurrent Infection. *Cold Spring Harbor Perspectives in Medicine*, 4(10), pp.a019729-a019729.

Fariz Kalista, K., Khie Chen, L., Wahyuningsih, R. and Martin Rumende, C. (2017). Karakteristik Klinis dan Prevalensi Pasien Kandidiasis Invasif di Rumah Sakit Cipto Mangunkusumo. *Jurnal Penyakit Dalam Indonesia*, [online] 4(2), pp.56-61.

Gulati, M. and Nobile, C. (2016). *Candida albicans* biofilms: development, regulation, and molecular mechanisms. *Microbes and Infection*, 18(5), pp.310-321.

Ham, Y. and Kim, T. (2016). Inhibitory activity of monoacylglycerols on biofilm formation in *Aeromonas hydrophila*, *Streptococcus mutans*, *Xanthomonas oryzae*, and *Yersinia enterocolitica*. *SpringerPlus*, 5(1).

Haque, F., Alfatah, M., Ganesan, K. and Bhattacharyya, M. (2016). Inhibitory Effect of Sophorolipid on *Candida albicans* Biofilm Formation and Hyphal Growth. *Scientific Reports*, 6(1).

Hess, D., Henry-Stanley, M. and Wells, C. (2014). Antibacterial Synergy of Glycerol Monolaurate and *Aminoglycosides* in *Staphylococcus aureus* Biofilms. *Antimicrobial Agents and Chemotherapy*, 58(11), pp.6970-6973.

Kamikawa, Y., Nagayama, T., Fujisaki, J., Hirabayashi, D., Kawasaki, K., Hamada, T., Mori, Y., Kamikawa, Y., Mukai, H., Sato, T. and Sugihara, K. (2013). Clinical study on anti-fungal drug activity against clinically isolated strains of oral *Candida* species. *Oral Science International*, 10(2), pp.87-94.

Kauffman, C. (2019). *UpToDate*. [online] Uptodate.com. Diakses melalui: <https://www.uptodate.com/contents/management-of-candidemia-and-invasive-kandidiasis-in-adults> [Accessed 17 Sep. 2019].

Kavanagh, K. (2005). *Jamur*. Chichester: Wiley, pp.32, 183.

Kementrian Kesehatan Republik Indonesia. (2015). *Formularium Nasional*. Jakarta

Kothavade, R., Kura, M., Valand, A. and Panthaki, M. (2010). *Candida tropicalis*: its prevalence, pathogenicity and increasing resistance to fluconazole. *Journal of Medical Microbiology*, 59(8), pp.873-880.

Lieberman, S., Enig, M. and Preuss, H. (2006). A Review of Monolaurin and Lauric Acid: Natural Virucidal and Bactericidal Agents. *Alternative and Complementary Therapies*, 12(6), pp.310-314.

- Liu, R., Shang, Z., Li, T., Yang, M. and Kong, L. (2017). In Vitro Antibiofilm Activity of Eucarobustol E against *Candida albicans*. *Antimicrobial Agents and Chemotherapy*, 61(8), pp.e02707-16.
- Lopes, L., Santos, C., Vaucher, R., Raffin, R. and Santos, R. (2016). Nanocapsules with glycerol monolaurate: Effects on *Candida albicans* biofilms. *Microbial Pathogenesis*, 97, pp.119-124.
- Marak, M. and Dhanashree, B. (2018). Antifungal Susceptibility and Biofilm Production of *Candida* spp. Isolated from Clinical Samples. *International Journal of Microbiology*, 2018, pp.1-5.
- Marioni, J., Bresolí-Obach, R., Agut, M., Comini, L., Cabrera, J., Paraje, M., Nonell, S. and Núñez Montoya, S. (2017). On the mechanism of *Candida tropicalis* biofilm reduction by the combined action of naturally-occurring anthraquinones and blue light. *PLOS ONE*, 12(7), p.e0181517.
- Muadcheingka, T. and Tantivitayakul, P. (2015). Distribution of *Candida albicans* and non-albicans *Candida* species in oral candidiasis patients: Correlation between cell surface hydrophobicity and biofilm forming activities. *Archives of Oral Biology*, 60(6), pp.894-901.
- Mueller, E. and Schlievert, P. (2015). Non-Aqueous Glycerol Monolaurate Gel Exhibits Antibacterial and Anti-Biofilm Activity against Gram-Positive and Gram-Negative Pathogens. *PLOS ONE*, 10(3), p.e0120280.

Mulyati, M., Wahyuningsih, R., Widiastuti, W., Sjarifuddin, P., 2010. *Candida* Isolation from Stools of HIV/AIDS Patients. *Makara Journal of Health Research*. 50–54.

Negri, M., Silva, S., Henriques, M., Azeredo, J., Svidzinski, T. and Oliveira, R. (2011). *Candida tropicalis* biofilms: artificial urine, urinary catheters and flow model. *Medical Mycology*, pp.1-9.

Nett, J., Lincoln, L., Marchillo, K., Massey, R., Holoyda, K., Hoff, B., VanHandel, M. and Andes, D. (2006). Putative Role of -1,3 Glucans in *Candida albicans* Biofilm Resistance. *Antimicrobial Agents and Chemotherapy*, 51(2), pp.510-520.

Nikolić, M., Vasić, S., \DJur\ d jević, J., Stefanović, O., Čomić, L., (2014). Antibacterial and anti-biofilm activity of ginger (*Zingiber Officinale* (Roscoe)) ethanolic extract. *Kragujevac Journal of Science*. pp. 129–136.

Nitbani, F., Jumina, Siswanta, D. and Solikhah, E. (2016). Isolation and Antibacterial Activity Test of Lauric Acid from Crude Coconut Oil (*Cocos nucifera* L.). *Procedia Chemistry*, 18, pp.132-140.

Ogbolu DO, Oni AA, Daini OA, Oloko AP. (2007). In vitro antimicrobial properties of coconut oil on candida species in Ibadan, Nigeria. *Journal of Medicinal Food*. ;10(2):384-387.

Pasko, M., Piscitelli, S. and Van Slooten, A. (1990). Fluconazole: A New Triazole Antifungal Agent. *Dalian Institute of Chemical Physics*, 24(9), pp.860-867.

Pfaller, M., Diekema, D. and Sheehan, D. (2006). Interpretive Breakpoints for Fluconazole and Candida Revisited: a Blueprint for the Future of Antifungal Susceptibility Testing. *Clinical Microbiology Reviews*, 19(2), pp.435-447.

Pierce, C., Uppuluri, P., Tristan, A., Wormley, F., Mowat, E., Ramage, G. and Lopez-Ribot, J. (2008). A simple and reproducible 96-well plate-based method for the formation of fungal biofilms and its application to antifungal susceptibility testing. *Nature Protocols*, 3(9), pp.1494-1500.

Puspitasari, A., Kawilarang, A., P., Ervianti, E., Rohiman, A. (2019). Profile of New Patients of Candidiasis. *Periodical of Dermatology and Venerology*, 31(1). pp. 24-34

Kim, S., Chen, J., Cheng, T., Gindulyte, A., He, J., He, S., Li, Q., Shoemaker, B., Thiessen, P., Yu, B., Zaslavsky, L., Zhang, J. and Bolton, E. (2018). PubChem 2019 update: improved access to chemical data. *Nucleic Acids Research*, 47(D1), pp.D1102-D1109.

Ramage, G., Rajendran, R., Sherry, L. and Williams, C. (2012). Fungal Biofilm Resistance. *International Journal of Microbiology*, 2012, pp.1-14.

- Sahal, G. and Bilkay, I. (2019). Distribution of clinical isolates of *Candida* spp. and antifungal susceptibility of high biofilm-forming *Candida* isolates.
- Samaranayake, Y., Ye, J., Yau, J., Cheung, B. and Samaranayake, L. (2005). In Vitro Method To Study Antifungal Perfusion in *Candida* Biofilms. *Journal of Clinical Microbiology*, 43(2), pp.818-825.
- Seleem, D., Chen, E., Benso, B., Pardi, V. and Murata, R. (2016). In vitro evaluation of antifungal activity of monolaurin against *Candida albicans* biofilms. *PeerJ*, 4, p.e2148.
- Shino, B., Peedikayil, F., Jaiprakash, S., Ahmed Bijapur, G., Kottayi, S. and Jose, D. (2016). Comparison of Antimicrobial Activity of Chlorhexidine, Coconut Oil, Probiotics, and Ketoconazole on *Candida albicans* Isolated in Children with Early Childhood Caries: An In Vitro Study. *Scientifica*, 2016, pp.1-5.
- Strandberg, K., Peterson, M., Lin, Y., Pack, M., Chase, D. and Schlievert, P. (2009). Glycerol Monolaurate Inhibits *Candida* and *Gardnerella vaginalis* In Vitro and In Vivo but Not *Lactobacillus*. *Antimicrobial Agents and Chemotherapy*, 54(2), pp.597-601.
- Tan, Y., Leonhard, M., Ma, S. and Schneider-Stickler, B. (2016). Influence of culture conditions for clinically isolated non-*albicans* *Candida* biofilm formation. *Journal of Microbiological Methods*, 130, pp.123-128.

- Taweechaisupapong, S., Ngaonee, P., Patsuk, P., Pitiphat, W. and Khunkitti, W. (2012). Antibiofilm activity and post antifungal effect of lemongrass oil on clinical *Candida dubliniensis* isolate. *South African Journal of Botany*, 78, pp.37-43.
- U. S. Food and Drug Administration, (2017). Code of Federal Regulations Title 21: Food and Drugs Chapter I : Food and Drug Administration. Department of Health and Human Services Subchapter B: Food for Human Consumption (Part 184 : Direct Food Substances Affirmed as Generally Recognized as Safe). *Silver Spring*: U.S. Food and Drug Administration.
- Vasudevan, R. (2014). Biofilms: Microbial Cities of Scientific Significance. *Journal of Microbiology & Experimentation*, 1(3).
- Wakharde, A., Halbandge, S., Phule, D. and Karuppayil, S. (2018). Anticancer Drugs as Antibiofilm Agents in *Candida albicans*: Potential Targets. *ASSAY and Drug Development Technologies*.
- Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. (2006). Drugbank: a comprehensive resource for in silico drug discovery and exploration. *Nucleic Acids Res.* 1;34 (Database issue):D668-72. 16381955.

Zhang, H., Wei, H., Cui, Y., Zhao, G. and Feng, F. (2009). Antibacterial Interactions of Monolaurin with Commonly Used Antimicrobials and Food Components. *Journal of Food Science*, 74(7), pp.M418-M421.

Zuza-Alves, D., Silva-Rocha, W. and Chaves, G. (2017). An Update on *Candida tropicalis* Based on Basic and Clinical Approaches. *Frontiers in Microbiology*, 8.